A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. See why AZN stock is a Buy.

We compared the dapagliflozin 10 mg (n = 179) and saxagliptin 5 mg (n = 176 ... This analysis was supported by AstraZeneca. Editorial support was provided by Shelley Narula of in Science ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN ... fell 41% and liquidity rose to $10.2 million. Ocean Power Technologies ...

BELGRADE, Serbia—Dapagliflozin (Farxiga; AstraZeneca) does not further improve quality of ... or impaired LVEF) to dapagliflozin 10 mg once daily or standard care, was the first trial to extend those ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action ...

The company sees a major opportunity for growth, estimating the market for R&I products increasing from $130 billion to $200 billion over the next 10 years. AstraZeneca chalks up double win for ...

AstraZeneca manufactures Farxiga, one of the drugs selected in the first round of drug price negotiations under the Program. Farxiga (dapagliflozin) is used to treat diabetes, heart disease ...